Side-by-side · Research reference

PNC-27vsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED18/41 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

PNC-27

p53-HDM-2 Peptide · Membrane-Targeting

32 AAPeptide lengthSarafraz-Yazdi 2022

12-26p53 domain

Pre-clinicalDevelopment stage

In vitro / Pre-clinical only

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

PNC-27

Teriparatide

Primary target

Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022 Krzesaj 2024

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024 Krzesaj 2024

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024 Krzesaj 2024

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

N/A — cytotoxic mechanism, not signaling modulation

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

PNC-27

Teriparatide

Clinical status

Pre-clinical only — no human trials

In vitro and animal model data only.

—

In vitro concentrations

10–100 μM range

Effective concentrations in cell culture studies.

—

Shorter analogue

PNC-28 (28 AA variant)

Retains HDM-2 binding and cytotoxic activity.

—

Evidence basis

Pre-clinical / In vitro

RCT / FDA-approved

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Frequency

—

Once daily

Intermittent administration preserves anabolic effect.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

PNC-27

Teriparatide

Fat loss mechanism

None — cytotoxic anticancer agent

—

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

PNC-27

Teriparatide

Human safety data

None available — no human trials conducted

—

Normal cell selectivity

In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010 Thadi 2020

Normal cells express minimal membrane HDM-2.

—

Cancer cell specificity

Depends on membrane HDM-2 expression levels

Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.

—

Cell death mechanism

Necrosis (not apoptosis) — rapid membrane lysisPincus 2024

—

Mitochondrial effects

Secondary mitochondrial membrane disruption in cancer cells

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

PNC-27

·Human use — no clinical trials or safety data

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

PNC-27

—

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

PNC-27

Teriparatide

1. Pre-clinical status

PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Cell culture protocols

In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Fluorescent labeling studies

Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Membrane HDM-2 requirement

Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Monitoring

—

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.